Enrico Pessina
Biographic Data
| ID | 7650819 |
|---|---|
| NAME | Enrico Pessina |
| GIVEN NAMES | Enrico |
| FAMILY NAME | Pessina |
| SIGNATURE | PESSINA E |
| AFFILIATIONS | Massachusetts Department of Mental Health |
| ORCID | 0000-0003-0485-6319 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Real-world outcomes of lurasidone augmentation for treatment-resistant bipolar depression
Lurasidone appears to be an effective and generally well-tolerated adjunctive option for TRBD. However, remission rates remained low, underscoring the need for further research. In this perspective, lurasidone may contribute to more individualized treatment strategies for difficult-to-treat patients, although confirmatory studies are required to better define its role within precision psychiatry
Efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD
This study provides preliminary evidence of the efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD. The observed improvements in OCD, depressive and anxiety symptoms suggest that vortioxetine may represent a valuable therapeutic option. Further prospective controlled trials are needed to confirm these findings
Cariprazine augmentation in patients with treatment resistant unipolar depression who failed to respond to previous atypical antipsychotic add-on. A case-series
Among individuals receiving an adequate pharmacological treatment for Major Depressive Disorder (MDD), only 30% reach a full symptom recovery; the remaining 70% will experience either a pharmacological response without remission or no response at all thus configuring treatment resistant depression (TRD). After an inadequate response to an antidepressant, possible next step options include optimizing the dose of the current antidepressant, switchi…
No prominent works on this page.
Cariprazine augmentation in patients with treatment resistant unipolar depression who failed to respond to previous atypical antipsychotic add-on. A case-series
Among individuals receiving an adequate pharmacological treatment for Major Depressive Disorder (MDD), only 30% reach a full symptom recovery; the remaining 70% will experience either a pharmacological response without remission or no response at all thus configuring treatment resistant depression (TRD). After an inadequate response to an antidepressant, possible next step options include optimizing the dose of the current antidepressant, switchi…
Efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD
This study provides preliminary evidence of the efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD. The observed improvements in OCD, depressive and anxiety symptoms suggest that vortioxetine may represent a valuable therapeutic option. Further prospective controlled trials are needed to confirm these findings
Real-world outcomes of lurasidone augmentation for treatment-resistant bipolar depression
Lurasidone appears to be an effective and generally well-tolerated adjunctive option for TRBD. However, remission rates remained low, underscoring the need for further research. In this perspective, lurasidone may contribute to more individualized treatment strategies for difficult-to-treat patients, although confirmatory studies are required to better define its role within precision psychiatry
Anxiety (3 works) · Adverse effect (2 works) · Antidepressant (2 works) · Depression (economics (2 works) · Electroconvulsive Therapy Studies (2 works) · Internal Medicine (2 works) · Major depressive disorder (2 works) · Medicine (2 works) · Psychiatry (2 works) · Tolerability (2 works)